[Latest] Global Clinical Trial Outsourcing Market Size/Share Worth USD 91,210.1 Million by 2033 at a 7.46% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 janv. 2025 08h10 HE
|
Custom Market Insights
Austin, TX, USA, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Clinical Trial Outsourcing Market Size, Trends and Insights By Services...
YPrime’s Karl McEvoy Appointed as eCOA Consortium Industry Co-Director for 2025
14 janv. 2025 08h00 HE
|
Y-Prime, LLC
YPrime's Dr. Karl McEvoy, VP eCOA & Patient Technologies, has been appointed Industry Co-Director of the Critical Path Institute (C-Path) eCOA Consortium
Franklin Access (Formerly Franklin Wireless) Successfully Defends Shareholder Litigation
24 déc. 2024 13h00 HE
|
Franklin Wireless Corporation
SAN DIEGO, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Franklin Access is pleased to announce a significant legal victory in its shareholder litigation, “In re Franklin Wireless Corp. Derivative Litigation”,...
BIOA BREAKING NEWS: BFA Law Announces an Investigation into BioAge Labs, Inc. after Stock Plummets 76% -- Contact the Firm if You Lost Money (NASDAQ:BIOA)
10 déc. 2024 12h49 HE
|
Bleichmar Fonti & Auld
BioAge Labs, Inc. investors that lost money are encouraged to contact BFA Law about its securities fraud investigation into the Company.
Tiziana Life Sciences Announces Groundbreaking ALS Trial Grant Awarded by the ALS Association
19 nov. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Legendary Attorney Glenn Zeitz Launches Podcast: Philly Trial Lawyer Stories
24 oct. 2024 10h00 HE
|
Glenn Zeitz
PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Philly Trial Lawyer Stories, a new podcast from legendary attorney Glenn Zeitz, is set to launch on October 23rd offering listeners an exclusive,...
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
30 sept. 2024 07h00 HE
|
CYTOMED THERAPEUTICS LIMITED
Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT SINGAPORE, Sept. 30, 2024 (GLOBE...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
10 juil. 2024 07h00 HE
|
OKYO Pharma LTD
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease...
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
04 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...